BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

280 related articles for article (PubMed ID: 37923987)

  • 21. Initial experience of preoperative short-course radiotherapy followed by oxaliplatin-based consolidation chemotherapy for locally advanced rectal cancer.
    Song SH; Park JS; Kang MK; Choi GS; Park SY; Kim HJ; Kim JG; Kang BW; Baek JH; Baek DW; Kim JC; Park SH; Cho SH; Seo AN
    Int J Colorectal Dis; 2021 Jun; 36(6):1279-1286. PubMed ID: 33547945
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Non-operative management after chemoradiotherapy plus consolidation or sandwich (induction with bevacizumab and consolidation) chemotherapy in patients with locally advanced rectal cancer: a multicentre, randomised phase II trial (NOMINATE trial).
    Akiyoshi T; Shinozaki E; Taguchi S; Chino A; Hiratsuka M; Tominaga T; Nonaka T; Toda S; Matoba S; Matsui S; Okabayashi K; Mukai T; Hiyoshi Y; Yamaguchi T; Nagasaki T; Yamaguchi K; Ueno M; Kuroyanagi H; Fukunaga Y; Ishizuka N; Konishi T;
    BMJ Open; 2022 Mar; 12(3):e055140. PubMed ID: 35304396
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Short-course radiotherapy combined with CAPOX and PD-1 inhibitor for the total neoadjuvant therapy of locally advanced rectal cancer: the preliminary single-center findings of a prospective, multicentre, randomized phase II trial (TORCH)].
    Wang YQ; Shen LJ; Wan JF; Zhang H; Wang Y; Wu X; Wang JW; Wang RJ; Sun YQ; Tong T; Huang D; Wang L; Sheng WQ; Zhang X; Cai GX; Xu Y; Cai SJ; Zhang Z; Xia F
    Zhonghua Wei Chang Wai Ke Za Zhi; 2023 May; 26(5):448-458. PubMed ID: 37217353
    [No Abstract]   [Full Text] [Related]  

  • 24. Single-arm, phase II study of intra-arterial chemotherapy plus total neoadjuvant therapy to optimise complete response in distal rectal cancer: a study protocol.
    Huang W; Huang P; Guo H; Huang Z; Wei M; Guo J; Lin C; Li Y; Luo B; Lin J; Wang L
    BMJ Open; 2023 Oct; 13(10):e075023. PubMed ID: 37798027
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Neoadjuvant chemotherapy with modified FOLFOXIRI for locally advanced rectal cancer to transform effectively EMVI and MRF from positive to negative: results of a long-term single center phase 2 clinical trial.
    Zhang W; Zhou H; Jiang J; Zhu Y; Zou S; Jiang L; Tang Y; Liang J; Sun Y; Jiang Z; Qu W; Li Y; Zhou A
    BMC Cancer; 2023 Jun; 23(1):592. PubMed ID: 37370032
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Oxaliplatin added to fluorouracil-based preoperative chemoradiotherapy and postoperative chemotherapy of locally advanced rectal cancer (the German CAO/ARO/AIO-04 study): final results of the multicentre, open-label, randomised, phase 3 trial.
    Rödel C; Graeven U; Fietkau R; Hohenberger W; Hothorn T; Arnold D; Hofheinz RD; Ghadimi M; Wolff HA; Lang-Welzenbach M; Raab HR; Wittekind C; Ströbel P; Staib L; Wilhelm M; Grabenbauer GG; Hoffmanns H; Lindemann F; Schlenska-Lange A; Folprecht G; Sauer R; Liersch T;
    Lancet Oncol; 2015 Aug; 16(8):979-89. PubMed ID: 26189067
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Organ Preservation in Rectal Adenocarcinoma: a phase II randomized controlled trial evaluating 3-year disease-free survival in patients with locally advanced rectal cancer treated with chemoradiation plus induction or consolidation chemotherapy, and total mesorectal excision or nonoperative management.
    Smith JJ; Chow OS; Gollub MJ; Nash GM; Temple LK; Weiser MR; Guillem JG; Paty PB; Avila K; Garcia-Aguilar J;
    BMC Cancer; 2015 Oct; 15():767. PubMed ID: 26497495
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Neoadjuvant intermediate-course versus long-course chemoradiotherapy in T3-4/N0+ rectal cancer: Istanbul R-02 phase II randomized study.
    Senyurek S; Saglam S; Saglam EK; Yanar H; Gok K; Tastekin D; Akbas CK; Sakin ND; Kartal GD; Balik E; Keskin M; Sanli Y; Gulluoglu M; Akgun Z
    Oncol Res; 2023; 31(5):689-696. PubMed ID: 37547762
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Oxaliplatin-Based Adjuvant Chemotherapy for Rectal Cancer After Preoperative Chemoradiotherapy (ADORE): Long-Term Results of a Randomized Controlled Trial.
    Hong YS; Kim SY; Lee JS; Nam BH; Kim KP; Kim JE; Park YS; Park JO; Baek JY; Kim TY; Lee KW; Ahn JB; Lim SB; Yu CS; Kim JC; Yun SH; Kim JH; Park JH; Park HC; Jung KH; Kim TW
    J Clin Oncol; 2019 Nov; 37(33):3111-3123. PubMed ID: 31593484
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Neoadjuvant chemotherapy with FOLFIRINOX and preoperative chemoradiotherapy for patients with locally advanced rectal cancer (UNICANCER-PRODIGE 23): a multicentre, randomised, open-label, phase 3 trial.
    Conroy T; Bosset JF; Etienne PL; Rio E; François É; Mesgouez-Nebout N; Vendrely V; Artignan X; Bouché O; Gargot D; Boige V; Bonichon-Lamichhane N; Louvet C; Morand C; de la Fouchardière C; Lamfichekh N; Juzyna B; Jouffroy-Zeller C; Rullier E; Marchal F; Gourgou S; Castan F; Borg C;
    Lancet Oncol; 2021 May; 22(5):702-715. PubMed ID: 33862000
    [TBL] [Abstract][Full Text] [Related]  

  • 31. ACRNaCT trial protocol: efficacy of adjuvant chemotherapy in patients with clinical T3b/T4, N+ rectal Cancer undergoing Neoadjuvant Chemoradiotherapy: a pathology-oriented, prospective, multicenter, randomized, open-label, parallel group clinical trial.
    Li Q; Luo D; Zhu J; Yang L; Liu Q; Ma Y; Liang L; Cai S; Zhang Z; Li X;
    BMC Cancer; 2019 Nov; 19(1):1117. PubMed ID: 31729964
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Postoperative Chemoradiotherapy With Capecitabine and Oxaliplatin vs Capecitabine for Stage II to III Rectal Cancer: A Randomized Clinical Trial.
    Li N; Zhu Y; Liu LY; Feng YR; Wang WL; Wang J; Wang H; Li GF; Tang Y; Hu C; Liu WY; Ren H; Wang SL; Wang WH; Song YW; Liu YP; Fang H; Tang Y; Lu NN; Chen B; Qi SN; Liu XF; Li YX; Jin J
    JAMA Netw Open; 2021 Nov; 4(11):e2136116. PubMed ID: 34846525
    [TBL] [Abstract][Full Text] [Related]  

  • 33. ShorTrip Trial: A Prospective, Multicentric Phase II Single-Arm Trial of Short-Course Radiotherapy Followed by Intensified Consolidation Chemotherapy With the Triplet FOLFOXIRI as Total Neoadjuvant Therapy in Locally Advanced Rectal Cancer.
    Borelli B; Conca V; Carullo M; Sainato A; Mattioni R; Manfredi B; Balestri R; Buccianti P; Morelli L; Rossi P; Vagli P; Prete AA; Luca F; Morano F; Donato SD; Salvatore L; Bengala C; Rossini D; Boni L; Antoniotti C; Cremolini C; Masi G; Moretto R
    Clin Colorectal Cancer; 2023 Sep; 22(3):339-343.e3. PubMed ID: 37429749
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Preoperative short-course radiotherapy versus combined radiochemotherapy in locally advanced rectal cancer: a multi-centre prospectively randomised study of the Berlin Cancer Society.
    Siegel R; Burock S; Wernecke KD; Kretzschmar A; Dietel M; Loy V; Koswig S; Budach V; Schlag PM
    BMC Cancer; 2009 Feb; 9():50. PubMed ID: 19200365
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Sequential short-course radiation therapy and chemotherapy in the neoadjuvant treatment of rectal adenocarcinoma.
    Jia AY; Narang A; Safar B; Zaheer A; Murphy A; Azad NS; Gearhart S; Fang S; Efron J; Warczynski T; Hacker-Prietz A; Meyer J
    Radiat Oncol; 2019 Aug; 14(1):147. PubMed ID: 31426827
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Preoperative chemoradiotherapy using tegafur/uracil, oral leucovorin, and irinotecan (TEGAFIRI) followed by oxaliplatin-based chemotherapy as total neoadjuvant therapy for locally advanced rectal cancer: the study protocol for a phase II trial.
    Abe S; Kawai K; Nozawa H; Sasaki K; Murono K; Emoto S; Yokoyama Y; Matsuzaki H; Nagai Y; Yoshioka Y; Shinagawa T; Sonoda H; Yamamoto Y; Oba K; Ishihara S
    BMC Cancer; 2023 May; 23(1):450. PubMed ID: 37198556
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Bevacizumab and Combination Chemotherapy in rectal cancer Until Surgery (BACCHUS): a phase II, multicentre, open-label, randomised study of neoadjuvant chemotherapy alone in patients with high-risk cancer of the rectum.
    Glynne-Jones R; Hava N; Goh V; Bosompem S; Bridgewater J; Chau I; Gaya A; Wasan H; Moran B; Melcher L; MacDonald A; Osborne M; Beare S; Jitlal M; Lopes A; Hall M; West N; Quirke P; Wong WL; Harrison M;
    BMC Cancer; 2015 Oct; 15():764. PubMed ID: 26493588
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Galunisertib plus neoadjuvant chemoradiotherapy in patients with locally advanced rectal cancer: a single-arm, phase 2 trial.
    Yamazaki T; Gunderson AJ; Gilchrist M; Whiteford M; Kiely MX; Hayman A; O'Brien D; Ahmad R; Manchio JV; Fox N; McCarty K; Phillips M; Brosnan E; Vaccaro G; Li R; Simon M; Bernstein E; McCormick M; Yamasaki L; Wu Y; Drokin A; Carnahan T; To Y; Redmond WL; Lee B; Louie J; Hansen E; Solhjem MC; Cramer J; Urba WJ; Gough MJ; Crittenden MR; Young KH
    Lancet Oncol; 2022 Sep; 23(9):1189-1200. PubMed ID: 35952709
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Application of short-course radiotherapy with total neoadjuvant therapy in the treatment of middle and low rectal cancer].
    Chen CJ; Yang CK; Jian JL; Guan S; Xie MM
    Zhonghua Yi Xue Za Zhi; 2023 Jan; 103(4):271-277. PubMed ID: 36660788
    [No Abstract]   [Full Text] [Related]  

  • 40. [Analysis on efficacy and safety of total neoadjuvant therapy in patients with locally advanced rectal cancer with high risk factors].
    Ouyang GL; Meng WJ; Shu P; Deng XB; Wu B; Jiang D; Zhuang H; Shen YL; Zhou ZG; Wang ZQ; Wang X
    Zhonghua Wei Chang Wai Ke Za Zhi; 2019 Apr; 22(4):349-356. PubMed ID: 31054549
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.